Showing results (861-870 of 895) with videos related to
Sort By:
Pageof 90
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 26, 2026
Compound EGFR mutations are predominantly PACC (P-loop and alpha-C helix compressing) mutations with increased responsiveness to second- vs third-generation tyrosine kinase inhibitorsXimeng Liu, Moses Stamboulian, Maxime Borgeaud, et al.Science Translational Medicine|September 4, 2020
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint componentsMonique B Nilsson, Huiying Sun, Jacqulyne Robichaux, et al.Molecular Cancer Therapeutics|May 13, 2026
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR MutationsYves A Millet, Alexander I Spira, Christina S Baik, et al.Nature Medicine|April 25, 2018
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancerJacqulyne P Robichaux, Yasir Y Elamin, Zhi Tan, et al.Global Change Biology|November 6, 2019
Refining the role of phenology in regulating gross ecosystem productivity across European peatlandsFranziska Koebsch, Oliver Sonnentag, Järvi Järveoja, et al.Journal of Advances in Modeling Earth Systems|October 26, 2020
PEAT-CLSM: A Specific Treatment of Peatland Hydrology in the NASA Catchment Land Surface ModelM Bechtold, G J M De Lannoy, R D Koster, et al.European Journal of Heart Failure|September 27, 2018
Impact of exercise-based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta-analysis of randomised trialsRod S Taylor, Sarah Walker, Neil A Smart, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 20, 2018
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i>-Mutant NSCLCXiuning Le, Sonam Puri, Marcelo V Negrao, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2017
The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung CancerTina Cascone, Li Xu, Heather Y Lin, et al.Science Translational Medicine|November 10, 2017
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockersMonique B Nilsson, Huiying Sun, Lixia Diao, et al.Pageof 90